Friday, 16 October 2026European Markets

AIRTHINGS Stock Was 15.22% Up Today

Loading stream...

(VIANEWS) - The Market ended the session with AIRTHINGS (AIRX.OL) jumping 15.22% to kr2.46 on Wednesday, following the last session's upward trend. Oslo Børs Benchmark Index_GI dropped 0.47% to kr1,210.96, following the last session's downward trend on what was a somewhat down trend trading session today.

About AIRTHINGS

Airthings ASA, a hardware-enabled software company, develop products and systems for monitoring indoor air quality, radon, and energy efficiency worldwide. It operates through Consumer, Business, and Professional segments. The Consumer segments sells air quality sensors to private customers through retail and e-commerce. Its Business segment provides air quality solutions to schools, office building, and other commercial buildings. The Professional segment sells measurement solutions, which enables inspectors and certified radon professionals to measure, analyze, and report on buildings; and offers rental of products and calibration services. In addition, it offers digital radon detectors as well as smart indoor air quality monitors and solutions. The company provides its products under the View Plus, Wave Plus, Wave Radon, Wave Mini, House Kit, Hub, Corentium Home, Plus, and Pro brands. Airthings ASA was incorporated in 2008 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, AIRTHINGS has a trailing twelve months EPS of kr-0.53.

Volume

Today's last reported volume for AIRTHINGS is 586126 which is 161.89% above its average volume of 223802.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, AIRTHINGS's stock is considered to be oversold (<=20).

More news about AIRTHINGS (AIRX.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com